Amedisys (AMED) Financials

$94.27 +0.64 (+0.68%)

As of 04/24/2025 04:00 PM Eastern

Annual Income Statements for Amedisys

This table shows Amedisys' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-3.02	37	30	119	127	184	209	119	-9.75	43
Consolidated Net Income / (Loss)	-2.31	38	31	120	128	185	210	118	-11	38
Net Income / (Loss) Continuing Operations	-1,292	38	31	120	128	185	210	118	-11	38
Total Pre-Tax Income	-0.31	62	81	159	170	211	280	160	40	86
Total Operating Income	-9.20	57	79	155	177	219	252	181	156	95
Total Gross Profit	541	585	608	353	411	437	981	963	991	488
Total Revenue	1,281	1,419	1,511	1,663	1,956	2,072	2,214	2,223	2,236	2,348
Operating Revenue	1,281	1,419	1,511	1,663	1,956	2,072	2,214	2,223	2,236	2,348
Total Cost of Revenue	740	834	903	1,309	1,545	1,635	1,233	1,260	1,246	1,860
Operating Cost of Revenue	726	834	903	1,309	1,545	1,635	1,233	1,260	1,246	1,860
Total Operating Expenses	1,839	528	529	198	233	217	729	782	834	393
Selling, General & Admin Expense	452	503	466	167	188	192	711	754	817	231
Depreciation Expense	20	20	17	13	18	29	31	25	18	18
Other Operating Expenses / (Income)	1,290	0.00	29	0.00	0.00	-34	-13	0.00	-	96
Impairment Charge	77	4.43	1.32	0.00	1.47	4.15	0.00	3.01	0.00	48
Total Other Income / (Expense), net	8.86	4.23	2.28	3.84	-7.06	-8.45	28	-21	-117	-8.32
Interest Expense	11	5.16	5.03	7.37	15	11	9.53	22	31	31
Interest & Investment Income	9.89	5.66	3.54	7.97	5.42	1.28	36	0.13	14	14
Other Income / (Expense), net	9.75	3.73	3.77	3.24	2.04	1.31	1.75	1.57	-100	8.07
Income Tax Expense	2.00	24	50	39	43	26	70	43	51	48
Net Income / (Loss) Attributable to Noncontrolling Interest	0.71	0.37	0.38	0.78	1.07	1.58	1.09	-0.91	-1.19	-5.07
Basic Earnings per Share	($0.09)	$1.12	$0.90	$3.64	$3.95	$5.64	$6.41	$3.65	($0.30)	$1.32
Weighted Average Basic Shares Outstanding	33.02M	33.20M	33.70M	32.79M	32.14M	32.56M	32.64M	32.52M	32.60M	32.72M
Diluted Earnings per Share	($0.09)	$1.10	$0.88	$3.55	$3.84	$5.52	$6.34	$3.63	($0.30)	$1.31
Weighted Average Diluted Shares Outstanding	33.02M	33.74M	34.30M	33.61M	32.99M	33.27M	32.97M	32.65M	32.60M	33.05M
Weighted Average Basic & Diluted Shares Outstanding	33.60M	33.30M	33.70M	32.80M	32.31M	32.85M	32.53M	32.55M	32.67M	38.37M

This table shows Amedisys' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	26	32	25	-80	26	19	14	32	17	-20
Consolidated Net Income / (Loss)	25	32	25	-80	26	19	15	33	17	-26
Net Income / (Loss) Continuing Operations	25	32	25	-80	26	19	15	33	17	-26
Total Pre-Tax Income	35	41	35	-62	38	29	27	49	29	-19
Total Operating Income	39	46	42	38	42	34	32	52	30	-20
Total Gross Profit	236	496	241	256	245	249	250	264	250	-276
Total Revenue	558	562	556	553	556	571	571	591	588	598
Operating Revenue	558	562	556	553	556	571	571	591	588	598
Total Cost of Revenue	322	66	315	297	312	321	322	327	338	874
Operating Cost of Revenue	322	66	315	297	312	321	322	327	338	874
Total Operating Expenses	197	450	199	218	202	215	218	212	220	-257
Selling, General & Admin Expense	188	457	195	213	198	211	214	208	215	-405
Depreciation Expense	5.48	5.23	4.44	4.73	4.44	4.14	4.27	4.39	4.77	4.57
Other Operating Expenses / (Income)	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	96
Total Other Income / (Expense), net	-4.11	-4.90	-7.67	-100	-4.26	-4.81	-4.39	-2.98	-1.34	0.40
Interest Expense	4.96	5.78	7.52	7.50	8.02	8.23	8.12	7.90	7.77	6.98
Interest & Investment Income	0.36	0.47	0.53	8.73	2.56	2.21	2.64	3.13	3.91	4.70
Other Income / (Expense), net	0.49	0.41	-0.68	-101	1.20	1.21	1.09	1.78	2.52	2.67
Income Tax Expense	9.42	9.79	9.80	18	12	10	13	17	12	6.29
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.24	-0.17	-0.34	-0.21	-0.34	-0.30	0.19	0.27	-0.40	-5.14
Basic Earnings per Share	$0.79	$0.98	$0.78	($2.46)	$0.80	$0.58	$0.44	$0.99	$0.52	($0.63)
Weighted Average Basic Shares Outstanding	32.48M	32.52M	32.56M	32.58M	32.62M	32.60M	32.67M	32.71M	32.75M	32.72M
Diluted Earnings per Share	$0.79	$0.96	$0.77	($2.46)	$0.79	$0.60	$0.44	$0.98	$0.51	($0.62)
Weighted Average Diluted Shares Outstanding	32.62M	32.65M	32.64M	32.58M	32.83M	32.60M	32.98M	33.05M	33.14M	33.05M
Weighted Average Basic & Diluted Shares Outstanding	32.49M	32.55M	32.56M	32.61M	32.63M	32.67M	32.68M	32.74M	32.75M	38.37M

This table details how cash moves in and out of Amedisys' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	19	2.70	56	-66	76	-13	-38	8.36	85	164
Net Cash From Operating Activities	108	62	106	223	202	289	189	133	137	222
Net Cash From Continuing Operating Activities	108	62	106	223	202	289	189	133	137	222
Net Income / (Loss) Continuing Operations	-2.31	38	31	120	128	185	210	118	-11	38
Consolidated Net Income / (Loss)	-2.31	38	31	120	128	185	210	118	-11	38
Depreciation Expense	20	20	17	13	18	29	31	25	24	26
Amortization Expense	0.96	0.74	0.74	0.80	0.87	0.87	0.92	0.99	0.99	0.99
Non-Cash Adjustments To Reconcile Net Income	108	27	28	26	37	71	-6.36	27	131	75
Changes in Operating Assets and Liabilities, net	-19	-23	29	63	18	3.21	-47	-37	-8.03	81
Net Cash From Investing Activities	-67	-52	-44	-22	-353	-287	-282	-94	35	-8.36
Net Cash From Continuing Investing Activities	-67	-52	-44	-22	-353	-287	-282	-94	35	-8.36
Purchase of Property, Plant & Equipment	-21	-16	-11	-6.56	-7.89	-5.33	-6.72	-7.22	-13	-7.37
Acquisitions	-69	-36	-34	-9.26	-345	-300	-270	-73	-0.35	-1.05
Purchase of Investments	-3.50	-1.04	-0.48	-7.14	-0.21	0.00	-5.00	-15	0.00	0.00
Sale of Property, Plant & Equipment	20	0.00	0.25	0.05	0.16	0.08	0.14	0.07	0.14	0.00
Divestitures	0.41	-	-	0.00	0.00	18	0.00	0.00	48	0.00
Sale and/or Maturity of Investments	6.23	0.23	0.62	0.72	0.45	0.10	0.14	0.25	0.20	0.06
Net Cash From Financing Activities	-21	-7.52	-5.54	-267	227	-15	55	-30	-88	-49
Net Cash From Continuing Financing Activities	-21	-7.50	-5.54	-267	227	-15	55	-30	-88	-49
Repayment of Debt	-184	-140	-5.32	-224	-206	-713	-564	-548	-99	-37
Repurchase of Common Equity	-4.58	-12	0.00	-181	0.00	0.00	-100	-17	0.00	0.00
Payment of Dividends	-0.44	-0.33	-0.22	-1.09	-1.06	-1.12	-1.75	-1.56	-2.67	-3.36
Issuance of Debt	163	135	0.00	138	438	684	791	535	23	0.00
Issuance of Common Equity	2.20	2.48	2.38	2.43	3.19	3.56	3.97	9.67	2.60	0.00
Other Financing Activities, net	2.47	7.65	-2.39	-0.62	-5.95	12	-75	-7.89	-11	-8.20
Cash Interest Paid	6.18	2.90	2.70	3.52	9.63	6.21	5.29	28	30	30
Cash Income Taxes Paid	-12	0.76	0.32	14	30	51	34	24	29	40

This table details how cash moves in and out of Amedisys' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-17	23	15	42	-17	45	-18	37	88	58
Net Cash From Operating Activities	-14	41	26	61	-9.84	60	-6.54	52	106	70
Net Cash From Continuing Operating Activities	-14	41	26	61	-9.84	60	-6.54	52	106	70
Net Income / (Loss) Continuing Operations	25	32	25	-80	26	19	15	33	17	-26
Consolidated Net Income / (Loss)	25	32	25	-80	26	19	15	33	17	-26
Depreciation Expense	5.48	5.23	5.69	6.20	6.06	5.89	6.14	6.36	6.84	6.71
Amortization Expense	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25
Non-Cash Adjustments To Reconcile Net Income	9.00	1.57	6.80	108	31	-14	7.14	7.92	5.72	55
Changes in Operating Assets and Liabilities, net	-54	2.29	-12	26	-72	50	-35	5.21	76	34
Net Cash From Investing Activities	-1.03	-1.87	46	-7.75	-1.05	-2.04	-3.07	-1.57	-2.45	-1.28
Net Cash From Continuing Investing Activities	-1.03	-1.87	46	-7.75	-1.05	-2.04	-3.07	-1.57	-2.45	-1.28
Purchase of Property, Plant & Equipment	-1.85	-2.03	-1.56	-7.85	-1.20	-2.10	-2.89	-1.57	-1.60	-1.31
Acquisitions	0.72	-	-0.35	-	-	-	-0.20	0.20	-	-1.05
Purchase of Investments	-	-	-	-	-	-	-	-	-0.85	1.05
Sale and/or Maturity of Investments	0.06	0.16	0.02	0.01	0.15	0.03	0.02	-	-	0.03
Net Cash From Financing Activities	-2.64	-16	-57	-11	-6.25	-13	-8.55	-14	-15	-11
Net Cash From Continuing Financing Activities	-2.64	-16	-57	-11	-6.25	-13	-8.55	-14	-15	-11
Repayment of Debt	-185	-72	-63	-21	-6.12	-8.90	-8.94	-9.44	-9.35	-9.63
Payment of Dividends	-0.45	-0.14	-1.09	-0.43	-0.90	-0.26	-0.76	-1.21	-0.61	-0.79
Issuance of Common Equity	2.11	4.71	0.82	1.31	1.70	-1.23	1.76	0.15	-	-1.91
Other Financing Activities, net	-4.65	0.75	-1.31	-6.16	-0.94	-3.03	-0.62	-3.58	-5.13	1.12
Cash Interest Paid	16	7.00	6.65	6.38	6.76	9.98	8.19	7.32	7.71	6.77
Cash Income Taxes Paid	0.61	0.43	0.35	15	8.50	4.81	0.83	18	9.60	12

This table presents Amedisys' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	682	734	813	717	1,263	1,567	1,857	1,976	2,060	2,139
Total Current Assets	175	215	311	224	351	362	357	389	497	632
Cash & Equivalents	28	30	86	20	30	82	43	41	126	303
Restricted Cash	-	-	-	0.00	66	1.55	3.08	14	12	0.00
Accounts Receivable	125	166	201	189	238	255	275	297	313	296
Prepaid Expenses	8.11	7.40	7.33	7.57	8.24	10	10	12	15	13
Other Current Assets	15	11	16	7.35	8.23	13	26	26	30	20
Plant, Property, & Equipment, net	43	37	31	29	28	24	18	16	42	42
Total Noncurrent Assets	464	482	471	464	884	1,181	1,482	1,571	1,521	1,465
Goodwill	262	289	320	329	659	933	1,196	1,287	1,245	1,214
Intangible Assets	44	47	46	44	65	74	111	101	103	81
Other Noncurrent Operating Assets	33	39	49	54	139	127	174	183	174	169
Total Liabilities & Shareholders' Equity	682	734	813	717	1,263	1,567	1,857	1,976	2,060	2,139
Total Liabilities	271	273	297	234	621	756	881	870	940	959
Total Current Liabilities	175	181	215	222	327	456	374	356	474	514
Short-Term Debt	5.00	5.20	11	1.61	9.93	10	13	15	36	38
Accounts Payable	26	30	25	29	31	43	38	44	28	40
Accrued Expenses	72	63	89	99	137	166	151	137	246	153
Current Employee Benefit Liabilities	73	82	90	93	121	147	141	125	137	152
Other Current Liabilities	-	-	-	0.00	28	90	31	34	26	132
Total Noncurrent Liabilities	96	92	82	12	294	300	506	514	467	444
Long-Term Debt	92	88	78	5.78	232	205	432	419	362	339
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	0.00	20	41	48
Other Noncurrent Operating Liabilities	4.46	3.70	3.79	6.23	62	96	74	74	64	57
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	410	461	516	483	642	811	976	1,107	1,120	1,180
Total Preferred & Common Equity	410	460	515	482	640	809	931	1,052	1,067	1,135
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	410	460	515	482	640	809	931	1,052	1,067	1,135
Common Stock	504	538	569	604	645	698	728	755	787	818
Retained Earnings	-68	-31	0.20	120	246	430	639	758	748	791
Treasury Stock	-27	-47	-54	-242	-251	-319	-436	-461	-469	-475
Noncontrolling Interest	0.87	0.94	1.11	1.05	1.06	1.52	45	55	53	45

This table presents Amedisys' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,982	1,947	1,982	2,027	2,090	2,117	2,139
Total Current Assets	389	406	427	467	526	556	580
Cash & Equivalents	18	49	95	78	108	150	245
Restricted Cash	14	20	16	16	12	7.48	0.00
Accounts Receivable	302	294	279	320	359	357	301
Prepaid Expenses	17	19	14	21	20	16	20
Other Current Assets	38	24	23	33	26	26	13
Plant, Property, & Equipment, net	17	33	36	40	43	45	42
Total Noncurrent Assets	1,576	1,508	1,519	1,521	1,521	1,517	1,517
Goodwill	1,285	1,245	1,245	1,245	1,245	1,245	1,245
Intangible Assets	104	100	105	104	102	101	100
Other Noncurrent Operating Assets	187	163	170	172	174	171	173
Total Liabilities & Shareholders' Equity	1,982	1,947	1,982	2,027	2,090	2,117	2,139
Total Liabilities	913	814	922	934	947	938	939
Total Current Liabilities	367	353	462	468	485	480	486
Short-Term Debt	13	27	31	35	37	38	37
Accounts Payable	46	40	39	35	36	27	32
Accrued Expenses	130	138	137	139	147	147	252
Current Employee Benefit Liabilities	145	123	123	127	132	136	138
Other Current Liabilities	34	25	132	132	132	132	26
Total Noncurrent Liabilities	545	461	459	466	462	459	453
Long-Term Debt	443	373	370	367	356	351	344
Noncurrent Deferred & Payable Income Tax Liabilities	16	23	28	35	43	47	48
Other Noncurrent Operating Liabilities	86	65	61	64	63	60	60
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,070	1,133	1,061	1,094	1,143	1,179	1,200
Total Preferred & Common Equity	1,016	1,079	1,007	1,040	1,088	1,125	1,148
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,016	1,079	1,007	1,040	1,088	1,125	1,148
Common Stock	751	759	769	777	795	803	810
Retained Earnings	726	783	703	729	762	795	812
Treasury Stock	-461	-463	-465	-466	-469	-473	-473
Noncontrolling Interest	54	54	54	54	54	54	53

This table displays calculated financial ratios and metrics derived from Amedisys' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	6.31%	10.84%	6.48%	10.01%	17.63%	5.93%	6.88%	0.41%	0.59%	5.01%
EBITDA Growth	-61.01%	278.08%	22.94%	72.23%	15.29%	25.87%	14.08%	-27.05%	-60.77%	58.66%
EBIT Growth	-97.90%	11,056.67%	34.81%	92.52%	13.34%	22.88%	15.00%	-28.12%	-68.81%	80.43%
NOPAT Growth	-142.22%	644.35%	-14.92%	293.03%	13.63%	44.59%	-1.91%	-29.72%	-132.51%	196.94%
Net Income Growth	-117.66%	1,727.64%	-18.46%	291.52%	6.47%	44.78%	13.49%	-44.00%	-109.29%	448.96%
EPS Growth	-123.08%	1,322.22%	-20.00%	303.41%	8.17%	43.75%	14.86%	-42.74%	-108.26%	536.67%
Operating Cash Flow Growth	264.47%	-42.24%	69.82%	111.37%	-9.61%	43.05%	-34.63%	-29.44%	2.93%	61.58%
Free Cash Flow Firm Growth	122.63%	-147.05%	470.65%	374.41%	-210.78%	120.31%	-752.86%	108.61%	209.32%	156.45%
Invested Capital Growth	-5.24%	9.28%	-1.00%	-9.46%	67.57%	19.71%	45.97%	8.12%	-7.28%	-9.07%
Revenue Q/Q Growth	3.04%	0.69%	3.41%	2.24%	3.51%	2.47%	0.39%	0.12%	0.39%	1.17%
EBITDA Q/Q Growth	23.27%	-8.46%	17.62%	3.69%	-9.18%	25.90%	-4.62%	-2.76%	-11.65%	-28.37%
EBIT Q/Q Growth	109.82%	-11.98%	24.21%	4.44%	2.45%	10.86%	-5.28%	-1.09%	-16.74%	-33.71%
NOPAT Q/Q Growth	16.75%	-3.25%	-26.90%	34.88%	1.49%	8.85%	-5.35%	0.27%	-933.34%	-54.02%
Net Income Q/Q Growth	61.80%	-9.82%	-29.24%	35.43%	0.20%	10.51%	-5.22%	-2.05%	-787.80%	-53.86%
EPS Q/Q Growth	57.14%	-12.70%	-29.03%	35.50%	0.52%	10.40%	-4.80%	-2.16%	-600.00%	-48.22%
Operating Cash Flow Q/Q Growth	16.73%	15.85%	3.55%	16.62%	5.86%	-3.12%	-24.33%	36.61%	16.50%	4.71%
Free Cash Flow Firm Q/Q Growth	-69.94%	87.88%	-0.83%	21.93%	9.92%	-19.79%	-111.67%	122.58%	-33.35%	7.12%
Invested Capital Q/Q Growth	14.93%	-1.41%	-3.38%	-3.64%	-4.38%	-1.17%	8.44%	-0.46%	-1.61%	-6.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	42.21%	41.21%	40.22%	21.24%	21.01%	21.08%	44.30%	43.31%	44.31%	20.78%
EBITDA Margin	1.68%	5.74%	6.63%	10.37%	10.17%	12.08%	12.89%	9.37%	3.65%	5.52%
Operating Margin	-0.72%	4.04%	5.19%	9.33%	9.07%	10.58%	11.38%	8.13%	6.99%	4.03%
EBIT Margin	0.04%	4.30%	5.44%	9.53%	9.18%	10.65%	11.46%	8.20%	2.54%	4.37%
Profit (Net Income) Margin	-0.18%	2.65%	2.03%	7.23%	6.54%	8.94%	9.49%	5.29%	-0.49%	1.63%
Tax Burden Percent	750.65%	61.12%	37.97%	75.56%	75.06%	87.84%	75.00%	73.45%	-27.60%	44.26%
Interest Burden Percent	-56.31%	100.88%	98.22%	100.38%	94.93%	95.58%	110.48%	87.88%	69.68%	84.03%
Effective Tax Rate	0.00%	38.82%	62.00%	24.44%	24.94%	12.16%	25.00%	26.55%	127.60%	55.74%
Return on Invested Capital (ROIC)	-1.31%	6.99%	5.72%	23.71%	21.19%	22.27%	16.30%	9.28%	-3.01%	3.18%
ROIC Less NNEP Spread (ROIC-NNEP)	3.35%	10.89%	8.34%	-32.00%	13.21%	16.92%	24.30%	5.41%	7.06%	0.97%
Return on Net Nonoperating Assets (RNNOA)	0.73%	1.65%	0.56%	0.33%	1.56%	3.23%	7.22%	2.03%	2.03%	0.14%
Return on Equity (ROE)	-0.57%	8.64%	6.28%	24.05%	22.76%	25.50%	23.52%	11.30%	-0.98%	3.32%
Cash Return on Invested Capital (CROIC)	4.08%	-1.88%	6.72%	33.64%	-29.31%	4.33%	-21.08%	1.47%	4.54%	12.68%
Operating Return on Assets (OROA)	0.08%	8.62%	10.63%	20.70%	18.13%	15.59%	14.82%	9.51%	2.82%	4.89%
Return on Assets (ROA)	-0.34%	5.32%	3.97%	15.70%	12.92%	13.09%	12.28%	6.14%	-0.54%	1.82%
Return on Common Equity (ROCE)	-0.57%	8.62%	6.26%	24.00%	22.71%	25.46%	22.91%	10.76%	-0.93%	3.18%
Return on Equity Simple (ROE_SIMPLE)	-0.56%	8.18%	5.95%	24.94%	19.97%	22.88%	22.57%	11.19%	-1.03%	3.36%
Net Operating Profit after Tax (NOPAT)	-6.44	35	30	117	133	193	189	133	-43	42
NOPAT Margin	-0.50%	2.47%	1.97%	7.05%	6.81%	9.30%	8.53%	5.97%	-1.93%	1.78%
Net Nonoperating Expense Percent (NNEP)	-4.65%	-3.90%	-2.62%	55.71%	7.98%	5.35%	-8.00%	3.87%	-10.07%	2.21%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	8.61%	-2.84%	2.69%
Cost of Revenue to Revenue	57.79%	58.79%	59.78%	78.76%	78.99%	78.92%	55.70%	56.69%	55.69%	79.22%
SG&A Expenses to Revenue	35.33%	35.47%	30.83%	10.04%	9.64%	9.27%	32.12%	33.92%	36.52%	9.85%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	143.65%	37.17%	35.03%	11.91%	11.93%	10.50%	32.92%	35.17%	37.31%	16.75%
Earnings before Interest and Taxes (EBIT)	0.55	61	82	158	180	221	254	182	57	103
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	22	81	100	172	199	250	285	208	82	130
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.23	3.11	3.47	7.75	8.41	11.89	5.67	2.58	2.91	2.62
Price to Tangible Book Value (P/TBV)	12.76	11.50	11.98	34.59	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.03	1.01	1.18	2.25	2.75	4.65	2.38	1.22	1.39	1.27
Price to Earnings (P/E)	0.00	38.41	59.03	31.29	42.45	52.42	25.24	22.89	0.00	68.78
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	2.60%	1.69%	3.20%	2.36%	1.91%	3.96%	4.37%	0.00%	1.45%
Enterprise Value to Invested Capital (EV/IC)	2.91	2.85	3.45	7.92	7.03	10.35	4.16	2.12	2.48	2.47
Enterprise Value to Revenue (EV/Rev)	1.09	1.05	1.19	2.24	2.83	4.71	2.58	1.42	1.53	1.32
Enterprise Value to EBITDA (EV/EBITDA)	64.74	18.35	17.90	21.59	27.82	38.99	20.04	15.13	41.79	23.86
Enterprise Value to EBIT (EV/EBIT)	2,549.79	24.49	21.79	23.50	30.81	44.24	22.56	17.28	60.05	30.14
Enterprise Value to NOPAT (EV/NOPAT)	0.00	42.64	60.09	31.76	41.52	50.66	30.29	23.73	0.00	73.91
Enterprise Value to Operating Cash Flow (EV/OCF)	12.94	24.01	16.95	16.66	27.38	33.77	30.29	23.64	24.89	13.95
Enterprise Value to Free Cash Flow (EV/FCFF)	69.40	0.00	51.13	22.39	0.00	260.75	0.00	149.69	52.46	18.53
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.24	0.20	0.17	0.02	0.38	0.27	0.46	0.39	0.36	0.32
Long-Term Debt to Equity	0.22	0.19	0.15	0.01	0.36	0.25	0.44	0.38	0.32	0.29
Financial Leverage	0.22	0.15	0.07	-0.01	0.12	0.19	0.30	0.37	0.29	0.15
Leverage Ratio	1.67	1.62	1.58	1.53	1.76	1.95	1.92	1.84	1.81	1.83
Compound Leverage Factor	-0.94	1.64	1.55	1.54	1.67	1.86	2.12	1.62	1.26	1.53
Debt to Total Capital	19.06%	16.78%	14.67%	1.51%	27.41%	20.96%	31.31%	28.21%	26.23%	24.23%
Short-Term Debt to Total Capital	0.99%	0.94%	1.75%	0.33%	1.12%	1.02%	0.91%	1.01%	2.39%	2.44%
Long-Term Debt to Total Capital	18.07%	15.85%	12.92%	1.18%	26.28%	19.94%	30.40%	27.21%	23.84%	21.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.17%	0.17%	0.18%	0.21%	0.12%	0.15%	3.16%	3.57%	3.51%	2.92%
Common Equity to Total Capital	80.77%	83.05%	85.15%	98.28%	72.47%	78.89%	65.52%	68.22%	70.26%	72.86%
Debt to EBITDA	4.49	1.14	0.89	0.04	1.22	0.86	1.56	2.09	4.87	2.91
Net Debt to EBITDA	3.21	0.77	0.02	-0.07	0.73	0.53	1.40	1.83	3.17	0.57
Long-Term Debt to EBITDA	4.25	1.08	0.78	0.03	1.17	0.82	1.51	2.01	4.43	2.62
Debt to NOPAT	-15.00	2.65	2.98	0.06	1.82	1.12	2.36	3.28	-9.22	9.02
Net Debt to NOPAT	-10.73	1.79	0.08	-0.11	1.09	0.68	2.11	2.87	-6.01	1.77
Long-Term Debt to NOPAT	-14.23	2.50	2.62	0.05	1.74	1.06	2.29	3.16	-8.38	8.11
Altman Z-Score	4.67	5.35	5.95	12.84	7.51	9.73	5.71	3.86	3.68	3.70
Noncontrolling Interest Sharing Ratio	0.18%	0.21%	0.21%	0.22%	0.19%	0.18%	2.60%	4.80%	4.86%	4.29%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.00	1.19	1.45	1.01	1.07	0.79	0.95	1.09	1.05	1.23
Quick Ratio	0.87	1.08	1.34	0.94	0.82	0.74	0.85	0.95	0.93	1.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	20	-9.46	35	166	-184	37	-244	21	65	167
Operating Cash Flow to CapEx	7,542.69%	396.13%	1,011.01%	3,436.09%	2,614.55%	5,501.75%	2,872.02%	1,864.36%	1,090.78%	3,006.44%
Free Cash Flow to Firm to Interest Expense	1.86	-1.83	6.97	22.56	-12.69	3.39	-25.65	0.95	2.08	5.43
Operating Cash Flow to Interest Expense	10.00	12.06	21.02	30.32	13.92	26.18	19.83	6.00	4.39	7.21
Operating Cash Flow Less CapEx to Interest Expense	9.86	9.01	18.94	29.44	13.38	25.70	19.14	5.67	3.98	6.97
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.90	2.01	1.95	2.17	1.98	1.46	1.29	1.16	1.11	1.12
Accounts Receivable Turnover	11.42	9.75	8.23	8.52	9.17	8.41	8.35	7.78	7.33	7.71
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	14.22	35.62	44.38	54.92	67.95	79.93	105.05	129.03	77.29	55.94
Accounts Payable Turnover	35.46	29.78	32.41	48.57	51.67	44.22	30.49	30.76	34.61	54.56
Days Sales Outstanding (DSO)	31.97	37.43	44.35	42.83	39.81	43.41	43.69	46.93	49.79	47.36
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	10.29	12.26	11.26	7.51	7.06	8.25	11.97	11.87	10.55	6.69
Cash Conversion Cycle (CCC)	21.68	25.17	33.09	35.31	32.74	35.16	31.73	35.07	39.25	40.67
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	480	524	519	470	787	942	1,376	1,487	1,379	1,254
Invested Capital Turnover	2.60	2.83	2.90	3.36	3.11	2.40	1.91	1.55	1.56	1.78
Increase / (Decrease) in Invested Capital	-27	45	-5.23	-49	317	155	433	112	-108	-125
Enterprise Value (EV)	1,395	1,495	1,792	3,723	5,531	9,757	5,722	3,150	3,415	3,093
Market Capitalization	1,325	1,431	1,789	3,734	5,384	9,624	5,278	2,714	3,102	2,973
Book Value per Share	$12.16	$13.71	$15.18	$15.10	$19.86	$24.66	$28.57	$32.36	$32.68	$34.64
Tangible Book Value per Share	$3.08	$3.71	$4.40	$3.39	($2.57)	($6.02)	($11.53)	($10.37)	($8.61)	($4.90)
Total Capital	507	554	605	490	884	1,026	1,421	1,541	1,518	1,557
Total Debt	97	93	89	7.39	242	215	445	435	398	377
Total Long-Term Debt	92	88	78	5.78	232	205	432	419	362	339
Net Debt	69	63	2.44	-13	146	132	399	381	259	74
Capital Expenditures (CapEx)	1.43	16	10	6.50	7.73	5.25	6.58	7.15	13	7.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-22	8.57	20	-17	-63	-167	-50	-5.21	-79	-148
Debt-free Net Working Capital (DFNWC)	5.07	39	107	3.25	34	-84	-4.60	49	60	156
Net Working Capital (NWC)	0.07	34	96	1.64	24	-94	-18	33	23	118
Net Nonoperating Expense (NNE)	-4.13	-2.57	-0.86	-2.90	5.30	7.42	-21	15	-32	3.68
Net Nonoperating Obligations (NNO)	69	63	2.43	-13	146	132	399	381	259	74
Total Depreciation and Amortization (D&A)	21	20	18	14	19	30	32	26	25	27
Debt-free, Cash-free Net Working Capital to Revenue	-1.75%	0.60%	1.35%	-1.02%	-3.22%	-8.07%	-2.28%	-0.23%	-3.55%	-6.28%
Debt-free Net Working Capital to Revenue	0.40%	2.73%	7.06%	0.20%	1.71%	-4.05%	-0.21%	2.20%	2.66%	6.63%
Net Working Capital to Revenue	0.01%	2.36%	6.36%	0.10%	1.21%	-4.55%	-0.79%	1.50%	1.04%	5.01%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.09)	$1.12	$0.90	$3.64	$3.95	$5.64	$6.41	$3.65	($0.30)	$1.32
Adjusted Weighted Average Basic Shares Outstanding	33.02M	33.20M	33.70M	32.79M	32.14M	32.56M	32.64M	32.52M	32.60M	32.72M
Adjusted Diluted Earnings per Share	($0.09)	$1.10	$0.88	$3.55	$3.84	$5.52	$6.34	$3.63	($0.30)	$1.31
Adjusted Weighted Average Diluted Shares Outstanding	33.02M	33.74M	34.30M	33.61M	32.99M	33.27M	32.97M	32.65M	32.60M	33.05M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	33.33M	33.61M	33.98M	32.01M	32.31M	32.85M	32.53M	32.55M	32.67M	38.37M
Normalized Net Operating Profit after Tax (NOPAT)	48	38	67	131	153	220	189	135	109	100
Normalized NOPAT Margin	3.72%	2.66%	4.45%	7.86%	7.83%	10.61%	8.53%	6.07%	4.90%	4.26%
Pre Tax Income Margin	-0.02%	4.34%	5.35%	9.56%	8.71%	10.18%	12.66%	7.21%	1.77%	3.67%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.05	11.82	16.35	21.49	12.37	19.98	26.63	8.20	1.82	3.34
NOPAT to Interest Expense	-0.60	6.79	5.93	15.91	9.18	17.45	19.84	5.97	-1.38	1.36
EBIT Less CapEx to Interest Expense	-0.08	8.77	14.27	20.61	11.83	19.51	25.94	7.88	1.42	3.10
NOPAT Less CapEx to Interest Expense	-0.73	3.75	3.85	15.02	8.65	16.97	19.14	5.65	-1.78	1.12
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-18.86%	0.87%	0.70%	0.91%	0.83%	0.61%	0.83%	1.33%	-24.44%	8.81%
Augmented Payout Ratio	-217.00%	33.56%	0.70%	151.91%	0.83%	0.61%	48.35%	16.07%	-24.44%	8.81%

This table displays calculated financial ratios and metrics derived from Amedisys' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.81%	0.49%	2.04%	-0.88%	-0.31%	1.55%	2.70%	6.91%	5.65%	4.78%
EBITDA Growth	-30.53%	-10.18%	-15.76%	-204.73%	10.14%	-20.66%	-17.93%	206.28%	-19.69%	-124.16%
EBIT Growth	-31.16%	-4.11%	-13.66%	-232.29%	10.12%	-24.50%	-21.56%	185.08%	-24.33%	-148.13%
NOPAT Growth	-38.11%	1.01%	-12.56%	-22.82%	0.32%	-37.22%	-44.27%	30.58%	-39.36%	-162.01%
Net Income Growth	-43.85%	-7.24%	-21.45%	-377.17%	0.84%	-39.71%	-41.41%	140.47%	-35.53%	-234.17%
EPS Growth	-42.34%	-7.69%	-20.62%	-370.33%	0.00%	-37.50%	-42.86%	139.84%	-35.44%	-203.33%
Operating Cash Flow Growth	-122.07%	691.39%	-46.61%	5.84%	27.78%	47.52%	-125.20%	-13.91%	1,173.09%	16.52%
Free Cash Flow Firm Growth	26.72%	80.81%	89.48%	127.54%	161.35%	270.60%	255.55%	-120.89%	-32.14%	-14.61%
Invested Capital Growth	17.78%	8.12%	5.24%	-6.52%	-6.19%	-7.28%	-3.36%	4.42%	-4.62%	-9.07%
Revenue Q/Q Growth	0.02%	0.73%	-1.01%	-0.61%	0.59%	2.62%	0.11%	3.46%	-0.59%	1.77%
EBITDA Q/Q Growth	-17.07%	15.46%	-8.61%	-219.68%	187.21%	-16.82%	-5.47%	55.00%	-34.10%	-125.03%
EBIT Q/Q Growth	-17.82%	18.33%	-10.62%	-252.20%	168.41%	-18.87%	-7.13%	65.07%	-39.16%	-151.60%
NOPAT Q/Q Growth	-17.14%	24.24%	-13.81%	-13.01%	7.70%	-22.25%	-23.50%	103.84%	-49.99%	-179.50%
Net Income Q/Q Growth	-12.52%	24.18%	-21.04%	-423.10%	131.83%	-25.75%	-23.27%	123.19%	-49.30%	-254.53%
EPS Q/Q Growth	-13.19%	21.52%	-19.79%	-419.48%	132.11%	-24.05%	-26.67%	122.73%	-47.96%	-221.57%
Operating Cash Flow Q/Q Growth	-123.74%	399.95%	-36.50%	134.04%	-116.20%	712.73%	-110.85%	899.65%	101.94%	-33.46%
Free Cash Flow Firm Q/Q Growth	54.98%	61.24%	44.42%	383.99%	0.27%	7.79%	-49.32%	-138.15%	425.64%	35.63%
Invested Capital Q/Q Growth	3.39%	-0.46%	-1.54%	-7.75%	3.76%	-1.61%	2.62%	-0.32%	-5.23%	-6.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	42.25%	88.27%	43.38%	46.21%	43.98%	43.69%	43.73%	44.70%	42.56%	-46.20%
EBITDA Margin	8.09%	9.27%	8.56%	-10.31%	8.94%	7.25%	6.84%	10.25%	6.80%	-1.67%
Operating Margin	6.98%	8.23%	7.62%	6.83%	7.59%	5.96%	5.53%	8.83%	5.16%	-3.28%
EBIT Margin	7.07%	8.30%	7.49%	-11.48%	7.80%	6.17%	5.72%	9.13%	5.59%	-2.83%
Profit (Net Income) Margin	4.55%	5.61%	4.48%	-14.55%	4.61%	3.33%	2.55%	5.51%	2.81%	-4.27%
Tax Burden Percent	72.96%	76.32%	71.77%	129.33%	67.50%	65.14%	53.60%	66.16%	56.97%	132.72%
Interest Burden Percent	88.33%	88.61%	83.24%	98.06%	87.41%	82.90%	83.24%	91.18%	88.24%	113.44%
Effective Tax Rate	27.04%	23.68%	28.23%	0.00%	32.50%	34.86%	46.40%	33.84%	43.03%	0.00%
Return on Invested Capital (ROIC)	8.18%	9.75%	8.55%	7.63%	7.88%	6.06%	4.64%	9.69%	4.98%	-4.10%
ROIC Less NNEP Spread (ROIC-NNEP)	7.38%	8.79%	6.98%	-23.08%	7.10%	5.08%	3.86%	8.93%	4.64%	-11.17%
Return on Net Nonoperating Assets (RNNOA)	2.72%	3.29%	2.28%	-7.66%	2.40%	1.46%	1.02%	2.08%	0.90%	-1.62%
Return on Equity (ROE)	10.90%	13.04%	10.83%	-0.03%	10.28%	7.52%	5.66%	11.77%	5.88%	-5.72%
Cash Return on Invested Capital (CROIC)	-6.75%	1.47%	3.89%	7.07%	6.75%	4.54%	-3.27%	3.08%	11.38%	12.68%
Operating Return on Assets (OROA)	8.00%	9.63%	8.69%	-12.85%	8.67%	6.84%	6.39%	10.20%	6.23%	-3.17%
Return on Assets (ROA)	5.16%	6.51%	5.19%	-16.29%	5.12%	3.69%	2.85%	6.15%	3.13%	-4.77%
Return on Common Equity (ROCE)	10.38%	12.42%	10.29%	-0.02%	9.77%	7.15%	5.39%	11.21%	5.61%	-5.47%
Return on Equity Simple (ROE_SIMPLE)	11.83%	0.00%	10.28%	0.14%	0.15%	0.00%	-1.95%	8.16%	7.21%	0.00%
Net Operating Profit after Tax (NOPAT)	28	35	30	26	28	22	17	35	17	-14
NOPAT Margin	5.09%	6.28%	5.47%	4.78%	5.12%	3.88%	2.97%	5.84%	2.94%	-2.30%
Net Nonoperating Expense Percent (NNEP)	0.81%	0.96%	1.57%	30.71%	0.79%	0.98%	0.78%	0.76%	0.34%	7.07%
Return On Investment Capital (ROIC_SIMPLE)	-	2.29%	-	-	-	1.46%	-	-	-	-0.88%
Cost of Revenue to Revenue	57.75%	11.73%	56.62%	53.79%	56.02%	56.31%	56.27%	55.30%	57.44%	146.20%
SG&A Expenses to Revenue	33.75%	81.34%	34.97%	38.52%	35.59%	37.01%	37.45%	35.12%	36.59%	-67.77%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	35.28%	80.04%	35.77%	39.37%	36.39%	37.73%	38.20%	35.87%	37.40%	-42.92%
Earnings before Interest and Taxes (EBIT)	39	47	42	-63	43	35	33	54	33	-17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	45	52	48	-57	50	41	39	61	40	-9.99
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.09	2.58	2.22	2.96	2.93	2.91	2.76	2.67	2.75	2.62
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.41	1.22	1.07	1.34	1.37	1.39	1.34	1.31	1.36	1.27
Price to Earnings (P/E)	25.97	22.89	21.34	1,277.78	1,150.14	0.00	0.00	32.61	38.10	68.78
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.85%	4.37%	4.69%	0.08%	0.09%	0.00%	0.00%	3.07%	2.62%	1.45%
Enterprise Value to Invested Capital (EV/IC)	2.42	2.12	1.90	2.46	2.43	2.48	2.36	2.33	2.51	2.47
Enterprise Value to Revenue (EV/Rev)	1.63	1.42	1.24	1.49	1.53	1.53	1.48	1.43	1.44	1.32
Enterprise Value to EBITDA (EV/EBITDA)	16.90	15.13	13.94	37.79	36.85	41.79	45.58	17.22	18.50	23.86
Enterprise Value to EBIT (EV/EBIT)	19.63	17.28	15.82	51.65	49.89	60.05	69.65	19.87	21.64	30.14
Enterprise Value to NOPAT (EV/NOPAT)	27.33	23.73	21.63	709.48	657.83	0.00	0.00	32.11	36.80	73.91
Enterprise Value to Operating Cash Flow (EV/OCF)	37.09	23.64	25.12	29.14	28.94	24.89	31.85	34.14	15.82	13.95
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	149.69	50.02	33.59	34.89	52.46	0.00	77.19	21.49	18.53
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.43	0.39	0.35	0.38	0.37	0.36	0.34	0.33	0.32	0.32
Long-Term Debt to Equity	0.41	0.38	0.33	0.35	0.34	0.32	0.31	0.30	0.29	0.29
Financial Leverage	0.37	0.37	0.33	0.33	0.34	0.29	0.27	0.23	0.19	0.15
Leverage Ratio	1.94	1.84	1.79	1.90	1.85	1.81	1.77	1.83	1.82	1.83
Compound Leverage Factor	1.72	1.63	1.49	1.86	1.62	1.50	1.48	1.67	1.60	2.07
Debt to Total Capital	29.89%	28.21%	26.09%	27.45%	26.89%	26.23%	25.61%	24.82%	24.14%	24.23%
Short-Term Debt to Total Capital	0.83%	1.01%	1.76%	2.15%	2.36%	2.39%	2.42%	2.41%	2.37%	2.44%
Long-Term Debt to Total Capital	29.06%	27.21%	24.34%	25.30%	24.53%	23.84%	23.18%	22.41%	21.77%	21.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	3.53%	3.57%	3.54%	3.69%	3.58%	3.51%	3.55%	3.42%	3.33%	2.92%
Common Equity to Total Capital	66.58%	68.22%	70.37%	68.86%	69.52%	70.26%	70.85%	71.76%	72.54%	72.86%
Debt to EBITDA	2.13	2.09	2.01	4.57	4.35	4.87	5.38	2.04	2.11	2.91
Net Debt to EBITDA	1.98	1.83	1.66	3.30	3.33	3.17	3.73	1.22	0.75	0.57
Long-Term Debt to EBITDA	2.07	2.01	1.87	4.21	3.97	4.43	4.87	1.84	1.90	2.62
Debt to NOPAT	3.44	3.28	3.11	85.73	77.65	-9.22	-4.08	3.80	4.20	9.02
Net Debt to NOPAT	3.21	2.87	2.58	61.99	59.50	-6.01	-2.83	2.27	1.50	1.77
Long-Term Debt to NOPAT	3.35	3.16	2.90	79.01	70.82	-8.38	-3.70	3.43	3.78	8.11
Altman Z-Score	3.78	3.63	3.58	3.43	3.63	3.64	3.57	3.65	3.74	3.52
Noncontrolling Interest Sharing Ratio	4.83%	4.80%	5.02%	5.11%	4.97%	4.86%	4.78%	4.81%	4.63%	4.29%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.06	1.09	1.15	0.92	1.00	1.05	1.09	1.16	1.19	1.23
Quick Ratio	0.87	0.95	0.97	0.81	0.85	0.93	0.96	1.06	1.12	1.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-197	-76	-42	121	121	130	66	-25	82	111
Operating Cash Flow to CapEx	-750.55%	2,014.93%	1,664.17%	773.90%	-821.62%	2,916.39%	-226.10%	3,329.41%	6,622.19%	5,348.33%
Free Cash Flow to Firm to Interest Expense	-39.74	-13.22	-5.65	16.08	15.08	15.84	8.14	-3.19	10.56	15.96
Operating Cash Flow to Interest Expense	-2.75	7.07	3.45	8.10	-1.23	7.32	-0.81	6.63	13.59	10.07
Operating Cash Flow Less CapEx to Interest Expense	-3.11	6.72	3.25	7.05	-1.38	7.07	-1.16	6.43	13.39	9.88
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.13	1.16	1.16	1.12	1.11	1.11	1.12	1.12	1.11	1.12
Accounts Receivable Turnover	7.70	7.78	7.60	7.63	7.16	7.33	6.89	7.20	7.48	7.71
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	118.02	129.03	88.23	82.20	78.33	77.29	59.22	56.50	56.87	55.94
Accounts Payable Turnover	32.02	30.76	43.21	36.79	37.43	34.61	32.83	39.32	39.22	54.56
Days Sales Outstanding (DSO)	47.43	46.93	48.00	47.82	50.96	49.79	52.97	50.67	48.80	47.36
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	11.40	11.87	8.45	9.92	9.75	10.55	11.12	9.28	9.31	6.69
Cash Conversion Cycle (CCC)	36.03	35.07	39.56	37.90	41.21	39.25	41.85	41.39	39.49	40.67
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,494	1,487	1,464	1,351	1,402	1,379	1,415	1,411	1,337	1,254
Invested Capital Turnover	1.61	1.55	1.56	1.59	1.54	1.56	1.56	1.66	1.70	1.78
Increase / (Decrease) in Invested Capital	226	112	73	-94	-92	-108	-49	60	-65	-125
Enterprise Value (EV)	3,619	3,150	2,779	3,321	3,407	3,415	3,335	3,285	3,349	3,093
Market Capitalization	3,140	2,714	2,394	2,977	3,046	3,102	3,007	3,000	3,160	2,973
Book Value per Share	$31.31	$32.36	$33.15	$30.92	$31.89	$32.68	$33.31	$34.40	$35.06	$34.64
Tangible Book Value per Share	($11.51)	($10.37)	($8.16)	($10.52)	($9.46)	($8.61)	($7.91)	($6.74)	($6.01)	($4.90)
Total Capital	1,526	1,541	1,534	1,462	1,496	1,518	1,536	1,568	1,582	1,557
Total Debt	456	435	400	401	402	398	393	389	382	377
Total Long-Term Debt	443	419	373	370	367	362	356	351	344	339
Net Debt	425	381	331	290	308	259	273	232	136	74
Capital Expenditures (CapEx)	1.82	2.03	1.56	7.85	1.20	2.07	2.89	1.57	1.60	1.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)	2.75	-5.21	10	-116	-60	-79	-42	-44	-114	-148
Debt-free Net Working Capital (DFNWC)	34	49	79	-4.39	34	60	79	114	131	156
Net Working Capital (NWC)	22	33	53	-36	-0.89	23	42	76	94	118
Net Nonoperating Expense (NNE)	3.00	3.74	5.50	107	2.88	3.13	2.35	1.97	0.76	12
Net Nonoperating Obligations (NNO)	425	381	331	290	308	259	273	232	136	74
Total Depreciation and Amortization (D&A)	5.73	5.48	5.94	6.45	6.31	6.14	6.39	6.61	7.08	6.96
Debt-free, Cash-free Net Working Capital to Revenue	0.12%	-0.23%	0.46%	-5.18%	-2.67%	-3.55%	-1.86%	-1.91%	-4.91%	-6.28%
Debt-free Net Working Capital to Revenue	1.54%	2.20%	3.56%	-0.20%	1.55%	2.66%	3.50%	4.96%	5.66%	6.63%
Net Working Capital to Revenue	0.97%	1.50%	2.35%	-1.61%	-0.04%	1.04%	1.85%	3.32%	4.05%	5.01%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.79	$0.98	$0.78	($2.46)	$0.80	$0.58	$0.44	$0.99	$0.52	($0.63)
Adjusted Weighted Average Basic Shares Outstanding	32.48M	32.52M	32.56M	32.58M	32.62M	32.60M	32.67M	32.71M	32.75M	32.72M
Adjusted Diluted Earnings per Share	$0.79	$0.96	$0.77	($2.46)	$0.79	$0.60	$0.44	$0.98	$0.51	($0.62)
Adjusted Weighted Average Diluted Shares Outstanding	32.62M	32.65M	32.64M	32.58M	32.83M	32.60M	32.98M	33.05M	33.14M	33.05M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	32.49M	32.55M	32.56M	32.61M	32.63M	32.67M	32.68M	32.74M	32.75M	38.37M
Normalized Net Operating Profit after Tax (NOPAT)	31	35	30	26	28	22	17	35	17	-14
Normalized NOPAT Margin	5.48%	6.28%	5.47%	4.78%	5.12%	3.88%	2.97%	5.84%	2.94%	-2.30%
Pre Tax Income Margin	6.24%	7.35%	6.24%	-11.25%	6.82%	5.12%	4.76%	8.33%	4.93%	-3.22%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	7.94	8.07	5.55	-8.46	5.41	4.28	4.03	6.84	4.23	-2.43
NOPAT to Interest Expense	5.72	6.10	4.05	3.53	3.55	2.69	2.09	4.38	2.22	-1.97
EBIT Less CapEx to Interest Expense	7.58	7.72	5.34	-9.51	5.26	4.03	3.67	6.64	4.02	-2.62
NOPAT Less CapEx to Interest Expense	5.36	5.75	3.84	2.48	3.40	2.44	1.73	4.18	2.02	-2.16
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	1.60%	1.33%	1.78%	152.36%	160.38%	-24.44%	-11.03%	3.40%	3.43%	8.81%
Augmented Payout Ratio	28.52%	16.07%	1.78%	152.36%	160.38%	-24.44%	-11.03%	3.40%	3.43%	8.81%

Frequently Asked Questions About Amedisys' Financials

When does Amedisys's fiscal year end?

According to the most recent income statement we have on file, Amedisys' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Amedisys' net income changed over the last 9 years?

Amedisys' net income appears to be on an upward trend, with a most recent value of $38.16 million in 2024, falling from -$2.31 million in 2015. The previous period was -$10.94 million in 2023.

What is Amedisys's operating income?

Amedisys's total operating income in 2024 was $94.54 million, based on the following breakdown:

Total Gross Profit: $487.93 million
Total Operating Expenses: $393.39 million

How has Amedisys revenue changed over the last 9 years?

Over the last 9 years, Amedisys' total revenue changed from $1.28 billion in 2015 to $2.35 billion in 2024, a change of 83.4%.

How much debt does Amedisys have?

Amedisys' total liabilities were at $958.75 million at the end of 2024, a 2.0% increase from 2023, and a 253.4% increase since 2015.

How much cash does Amedisys have?

In the past 9 years, Amedisys' cash and equivalents has ranged from $20.23 million in 2018 to $303.24 million in 2024, and is currently $303.24 million as of their latest financial filing in 2024.

How has Amedisys' book value per share changed over the last 9 years?

Over the last 9 years, Amedisys' book value per share changed from 12.16 in 2015 to 34.64 in 2024, a change of 185.0%.

Related Companies

This page (NASDAQ:AMED) was last updated on 4/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amedisys (AMED) Financials

Frequently Asked Questions About Amedisys' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amedisys (AMED) Financials

Annual Income Statements for Amedisys

Quarterly Income Statements for Amedisys

Annual Cash Flow Statements for Amedisys

Quarterly Cash Flow Statements for Amedisys

Annual Balance Sheets for Amedisys

Quarterly Balance Sheets for Amedisys

Annual Metrics and Ratios for Amedisys

Quarterly Metrics and Ratios for Amedisys

Frequently Asked Questions About Amedisys' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools